Overview

• Acelyrin, a pharmaceutical company, is facing a class action lawsuit filed on behalf of investors who purchased the company's securities between May 4, 2023, and September 11, 2023.
• The lawsuit alleges that Acelyrin made misleading statements and omissions about the effectiveness of its lead drug candidate, izokibep, in treating Hidradenitis Suppurativa (HS).
• On September 11, 2023, Acelyrin announced disappointing results from a trial of izokibep, which failed to show a significant reduction in abscesses and inflammatory nodules in patients compared to a placebo.
• Following the announcement, Acelyrin's stock price fell by 61.61%, closing at $10.71 per share on September 13, 2023.
• Investors who suffered significant losses are encouraged to contact law firms Kaplan Fox & Kilsheimer LLP, Kessler Topaz Meltzer & Check, LLP, and Rosen Law Firm before the lead plaintiff deadline of January 16, 2024.